RecruitingNot Applicable

Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

Hong Kong100 participantsStarted 2012-06-01

Plain-language summary

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation * Willing to give informed consent Exclusion Criteria: * Patients with co-existing renal diseases

What they're measuring

Hepatorenal syndrome

Timeframe: 12 weeks

Trial details

NCT IDNCT02434445

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-12-31

Contact for this trial

Desmond Yap, MD

85222553879 desmondy@hku.hk

View on ClinicalTrials.gov More Hepatorenal Syndrome trials